REGN•benzinga•
Regeneron Highlights Dupixent (dupilumab) Late-Breaking Phase 3 Data At The EADV 2022 Congress; Says Data Show Significant Improvements In Signs And Symptoms Of Prurigo Nodularis
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 8, 2022 by benzinga